RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
RedHill Biopharma (RDHL) Tops Q3 EPS by 21c, Revenues Miss
November 12, 2020 7:03 AM ESTRedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of $0.05, $0.21 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $25.37 million.
Financial highlights for the third quarter ended September 30, 20201
Net Revenues of $20.9 million, continuing at a similar level to that in the second quarter of 2020. The increase in gross revenues, as well as in the number of scripts for Talicia and Movantik, were partially offset by the voluntary discontinuation of our legacy products.Cost of Revenues of $10.3 million, compared to $14.2 million in the... More